Denali Therapeutics Inc. DNLI Finance Lease Right Of Use Asset Amortization
Finance Lease Right Of Use Asset Amortization at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAssetAmortization.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s finance lease right of use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s finance lease right of use asset amortization?
- Denali Therapeutics Inc. (DNLI) reported finance lease right of use asset amortization of $916K in Q1 2026.
- How has Denali Therapeutics Inc.'s finance lease right of use asset amortization changed year-over-year?
- Denali Therapeutics Inc.'s finance lease right of use asset amortization increased by 3.3% year-over-year, from $887K to $916K.
- What does finance lease right of use asset amortization mean?
- This represents the periodic non-cash charge to earnings resulting from the systematic allocation of the cost of a right-of-use asset acquired under a finance lease over its useful life. It is a key adjustment in the cash flow statement to reconcile net income with operating cash flows. Tracking this provides insight into the company's capital intensity and the long-term cost of its leased infrastructure.